Slide 1: Q2 FY-2025 Earnings Call
Q2 FY-2025 Earnings Call (o) Enabling the Future of Medicine
Slide 2: Forward Looking Statements
Forward Looking Statements Statements in this presentation which are not purely historical, including statements regarding Cryoport's intentions, hopes, beliefs, expectations, representations, projections, plans, or predictions of the future, are forward-looking statements within the meaning of the
Slide 3: Cryoport – Trusted Partner to Life Sciences Companies
Cryoport – Trusted Partner to Life Sciences Companies Life sciences company focused on providing mission critical, proprietary temperature-controlled supply chain solutions Capabilities include core competencies to ship, store and deliver biologics in a cryogenic or temperature-controlled state such
Slide 4: Cryoport – Q2 2025 Snapshot
Cryoport – Q2 2025 Snapshot (all data from continuing operations) Performance Recent News Strategic Partnership with DHL Group and all cash divestiture of CRYOPDP $426M specialty courier $45.5M $165 - $172M completed June 2025 +14% YoY growth FY 2025 Revenue Cash & Short-Term Q2-2025 Revenue Guidanc
Slide 5: Revenue by the Numbers
Revenue by the Numbers © 2025 CRYOPORT, INC. 5
Slide 6: Driving Bottom-Line Improvement
Driving Bottom-Line Improvement © 2025 CRYOPORT, INC. 6
Slide 7: LS Services Key Revenue Growth Drivers
LS Services Key Revenue Growth Drivers Commercial CGT Revenue BioStorage/BioServices ($ in millions) Revenue ($ in millions) $8.7 $4.5 $6.5 $3.5 +33% YoY +28% YoY Q2 2024 Q2 2025 Q2 2024 Q2 2025 © 2025 CRYOPORT, INC. 7
Slide 8: Cryoport Systems’ Clinical Trial Support
Cryoport Systems’ Clinical Trial Support Q2 2025: 82 Phase III Clinical Trials Supported by Cryoport • 728 clinical trials (net) in aggregate • 82 Phase III trials in the Americas, EMEA, and APAC Clinical Trials Supported by Trial Phase as of 6/30/25 Increased by 44 trials (net) over Q2-2024 Source:
Slide 9: Cryoport Systems’ Commercial Support Total Products
Cryoport Systems’ Commercial Support 18 Total Products AKUUGO® © 2025 CRYOPORT, INC. 9
Slide 10: Cryoport, Inc. is the Global Leader of Supply Chain Solutions for the Life Sciences
Cryoport, Inc. is the Global Leader of Supply Chain Solutions for the Life Sciences 728 15+ Active Cell & Gene Therapy ~70% Locations in Americas, EMEA and APAC Clinical Trials Supported1 Of All Industry Clinical Trials Supported1 with 670+ people2 18 1,200+ 1M+ Commercial Cell and Gene Therapies Su
Slide 11: Cryoport’s Platform Solution
Cryoport’s Platform Solution Comprehensive Supply Chain Management © 2025 CRYOPORT, INC. 11
Slide 12: Cryoport’s Logistics Management Made Easy
Cryoport’s Logistics Management Made Easy It’s as simple as a couple of clicks • Log into the Cryoportal® to create an order or select a prepopulated template • Carrier options, such as our Cryoshuttle®, integrators, and couriers or any combination to meet your specific shipment need are available •
Slide 13: Cryoport Systems’ Robust Shipper Fleet
Cryoport Systems’ Robust Shipper Fleet Packaging Cryoport Express® Standard Cryogenic Combo Shipper Cryoport Express® Cryoport ExpressStandard ® Cryogenic Cryoport Express ® Cryogenic CXCB1 Cryoport Express® Cryogenic Cryoport Express® Cryogenic Cryoport Express® Sliderite® Cryogenic Shipper ST1 Shi
Slide 14: Chain of Compliance
Chain of Compliance® • Traceability of the equipment and processes used in managing the environmental control of the biomaterials o Serialization of the shipper and components o 100% shipper (re)qualification o Performance history of shipper and courier o Commodity history for every shipper o Deviat
Slide 15: What Cryoport BioServices Offers
What Cryoport BioServices Offers: Regulatory & GMP Storage Consulting Services Drug Packaging Biobanking & Labelling Clinical Sample Kit Production Management Drug Recall, Return, Logistics Management & Destruction Services © 2025 CRYOPORT, INC. 15
Slide 16: Cryoport BioServices Value Proposition
Cryoport BioServices Value Proposition Expert Support We Collect We Protect We Transport We Comply A Dedicated Using our specialized Guaranteeing the safety of Ensuring your shipment Giving you full end-to-end Program Manager kitting, our experts collect your materials through is transported complia
Slide 17: IntegriCell Offering
IntegriCell Offering Cryopreservation Services & Process Development • Ready-to-use leukapheresis cryopreservation protocol • Technology transfer of client cryopreservation processes to IntegriCell teams and facilities • Customized cryopreservation process development services to meet client needs T
Slide 18: IntegriCell Current Footprint
IntegriCell Current Footprint Villers-le-Bouillet, Liège, BELGIUM Houston, USA CRYO Manufacturing CRYO Manufacturing • Cryopreservation Process Development • Cryopreservation Manufacturing for Clinical Grade/GMP • Cryopreservation Manufacturing for Clinical Grade/GMP compliant (1,000 units/year) com
Slide 19: IntegriCell Logistics Flow
IntegriCell Logistics Flow © 2025 CRYOPORT, INC. 19
Slide 20: MVE At A Glance
MVE At A Glance The Leading Cryogenic Systems Manufacturer in the World MVE Biological Solutions is the global Headquarters: Ball Ground, GA leading manufacturer of cryogenic systems, providing cryogenic freezers, dewars, and 270 employees globally related equipment used for cryogenic storage and tr
Slide 21: MVE’s Product Family
MVE’s Product Family CRYOGENIC FREEZERS Ball Ground, GA Bulk storage stainless-steel freezers in a range of sizes and configurations Basic bulk storage stainless-steel freezer for the breeder market CRYOGENIC DEWARS Chengdu, China Complete portfolio of aluminum dewars for sample storage, sample ship
Slide 22: MVE is FDA Registered
MVE is FDA Registered MVE is the only cryogenic storage manufacturer with FDA Registration, delivering cryogenic solutions that meet the highest regulatory standards, ensuring the safety of your valuable biological samples. © 2025 MVE BIOLOGICAL SOLUTIONS® CONFIDENTIAL | 22
Slide 23: CRYOGENE Houston
CRYOGENE Houston Secure GMP compliant biorepository • Facility is above the 500-year flood plain and windows rated to 110 MPH winds • 8 generators supply emergency back up power to the entire facility, including HVAC • Natural disasters – in the past 20 years, 2 major hurricanes (wind and flooding e
Slide 24: CRYOGENE Will Be Exclusive Supplier to Speros/Moffitt Cancer Center
CRYOGENE Will Be Exclusive Supplier to Speros/Moffitt Cancer Center • 30,000 sq ft facility with exclusivity for biorepository services • Construction to begin Q2 2025 • Biological material transfers begin Q2 2026 • CRYOGENE will provide our services to biotech, research, and pharma companies in the
Slide 25: A Unified Network Supporting the Life Sciences
A Unified Network Supporting the Life Sciences HQ © 2025 CRYOPORT, INC. 25
Slide 26: Partnership and Transaction with DHL Group
Partnership and Transaction with DHL Group © 2025 CRYOPORT, INC. 26
Slide 27: Our New Partnership with DHL Group
Our New Partnership with DHL Group Brings together DHL’s global health logistics capabilities with Cryoport's industry-leading expertise in providing specialized solutions • We share a common purpose: delivering life-preserving therapies and enabling the life sciences, improving lives around the wor
Slide 28: DHL in Figures – LSH Market
DHL in Figures – LSH Market DHL Life Sciences & Healthcare Global Network Number of Operations Global network with >580 locations handling 588 LSH shipments GDP Operations >11,000 LSH trained colleagues 257 (For DGF – GXP certification) €2bn investment to Total Temp-Controlled Storage (sq. m) 2030 2
Slide 29: Q2 2025 Revenue
Q2 2025 Revenue © 2025 CRYOPORT, INC. 29
Slide 30: Q2 Balance Sheet
Q2 Balance Sheet © 2025 CRYOPORT, INC. 30